Impact of non-alcoholic fatty liver disease on chronic hepatitis B

被引:106
作者
Bondini, Silvia
Kallman, Jillian
Wheeler, Angela
Prakash, Shivaani
Gramlich, Terry
Jondle, Daniel M.
Younossi, Zobair M.
机构
[1] Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA
[2] AmeriPath, Cleveland, OH USA
关键词
HBV; metabolic syndrome; NAFLD;
D O I
10.1111/j.1478-3231.2007.01482.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The impact of superimposed non-alcoholic fatty liver disease (NAFLD) is well established in patients with chronic hepatitis C (CH-C), but the impact in patients with chronic hepatitis B (CH-B) is less clear. Background: This study aims to evaluate the prevalence of NAFLD in patients with CH-B and the association with viral and host factors, particularly in patients with metabolic syndrome (MS). Aim: Data from patients with CH-B was obtained from our databases. Patients with excessive alcohol use were excluded. Hepatitis B virus (HBV) genotyping by INNO-LIPA was available for some patients. The presence of MS was defined according to the Adult Treatment Panel III (ATP III). All biopsies were read by two hepatopathologists using Metavir, modified histologic activity index (MHAI), as well as a NAFLD pathologic protocol. Patients were classified as (1) those without NAFLD; (2) those with simple hepatic steatosis; (3) and those with superimposed non-alcoholic steatohepatitis (NASH). Factors associated with superimposed NAFLD, its subtypes, and hepatic fibrosis were also analysed. Results: Subjects included 153 HBV patients [66% male, age 50.5 +/- 27.5 years, body mass index 24.7 +/- 3.7 kg/m(2), waist 83.2 +/- 10.9 cm; 8.5% Caucasian, 67% Asian, aspartate aminotransferase (AST) 63.2 +/- 88.2 IU/l, alanine aminotransferase (ALT) 98.6 +/- 164.6 IU/l, glucose 111.6 +/- 50.5 mg/dl, HBV-DNA 1.8 x 10(8)+/- 1.9 x 10(6) copies/ml, 7% with MS, 13% with diabetes, 20% with arterial hypertension and 8.5% with dyslipidaemia]. Liver biopsy was available for 64 subjects [19% had superimposed NAFLD, 13% had superimposed NASH, 86% had some degree of fibrosis, and 39% had advanced fibrosis (Ishak > 3)]. Patients with HBV and superimposed NASH were significantly older (55 vs. 42 years, P=0.008), more likely to have hypertension (63% vs. 15%, P=0.006) and dyslipidaemia (50% vs. 8%, P=0.006), and had a larger waist circumference (92 vs. 83 cm, P=0.03). The presence of fibrosis was associated with higher waist circumference (84 vs. 80 cm, P=0.03), higher HBV-DNA (1.9 x 10(8) vs. 5 x 10(6) copies/ml, P=0.005), and elevated ALT > 40 IU/l (73.6% vs. 33.3%, P=0.02). Conclusions: The components of MS (obesity, hypertension, and dyslipidaemia) are associated with the presence of NASH in patients with CH-B. The presence of hepatic fibrosis seems to be associated with known host and viral factors as well as the presence of abdominal obesity.
引用
收藏
页码:607 / 611
页数:5
相关论文
共 21 条
  • [1] Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity
    Adinolfi, LE
    Gambardella, M
    Andreana, A
    Tripodi, MF
    Utili, R
    Ruggiero, G
    [J]. HEPATOLOGY, 2001, 33 (06) : 1358 - 1364
  • [2] ALTLPARMAK F, 2005, WORLD J GASTROENTERO, V11, P3056
  • [3] An algorithm for the grading of activity in chronic hepatitis C
    Bedossa, P
    Poynard, T
    [J]. HEPATOLOGY, 1996, 24 (02) : 289 - 293
  • [4] High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C
    Bressler, BL
    Guindi, M
    Tomlinson, G
    Heathcote, J
    [J]. HEPATOLOGY, 2003, 38 (03) : 639 - 644
  • [5] Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease
    Brunt, EM
    Ramrakhiani, S
    Cordes, BG
    Neuschwander-Tetri, BA
    Janney, CG
    Bacon, BR
    Di Bisceglie, AM
    [J]. MODERN PATHOLOGY, 2003, 16 (01) : 49 - 56
  • [6] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [7] Fattovich Giovanna, 2003, Journal of Hepatology, V39, pS50
  • [8] Mechanisms of disease: Hepatitis B virus infection - Natural history and clinical consequences
    Ganem, D
    Prince, AM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) : 1118 - 1129
  • [9] Hepatic steatosis in chronic hepatitis B and C: Predictors, distrihution and effect on fibrosis
    Gordon, A
    McLean, CA
    Pedersen, JS
    Bailey, MJ
    Roberts, SK
    [J]. JOURNAL OF HEPATOLOGY, 2005, 43 (01) : 38 - 44
  • [10] Pathologic features associated with fibrosis in nonalcoholic fatty liver disease
    Gramlich, T
    Kleiner, DE
    McCullough, AJ
    Matteoni, CA
    Boparai, N
    Younossi, ZM
    [J]. HUMAN PATHOLOGY, 2004, 35 (02) : 196 - 199